Early octa changes of type 3 macular neovascularization following brolucizumab intravitreal injections

HIGHLIGHTS

• who: Anthony Gigon et al. from the Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland have published the Article: Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections, in the Journal: Medicina 2022, 1180 of /2022/
• what: We have shown a good short-term efficacy of brolucizumab IVI on OCTA in patients with early stage type 3 MNV in the context of nAMD.
• future: Studies are needed to validate the long-term efficacy of this approach. This is a pilot study and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.